10 Feb 2025
Alephoson’s CEO and Founder, Dr. Benjamin Lee, was interviewed by the SOUTH CHINA MORNING POST (SCMP), a leading Hong Kong newspaper, on Eye-Drug Delivery Technology and Clinical Trials.
“As a research-and-development-focused company, we are forging partnerships with university hospitals in Hong Kong, mainland China, Asia and the United States on our planned clinical trials”
“Upon completion of a preclinical toxicity study in around 12 months, our target is to request authorization from the US Food and Drug Administration to conduct Phase 1 and 2a investigational drug trials by the first quarter of next year.”
Read the full article here
Title: Hong Kong biotech start-up Alephoson eyes international trial for eye-drug delivery
